US 12,257,251 B2
Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation
Zaiqi Wang, Shanghai (CN); Jiangwei Zhang, Shanghai (CN); and Jun Jiang, Beijing (CN)
Assigned to INXMED (NANJING) CO., LTD., Nanjing (CN)
Filed by INXMED (NANJING) CO., LTD., Nanjing (CN)
Filed on Jul. 11, 2023, as Appl. No. 18/350,303.
Application 18/350,303 is a continuation of application No. 17/777,769, previously published as PCT/CN2020/129350, filed on Nov. 17, 2020.
Claims priority of application No. 201911128794.9 (CN), filed on Nov. 18, 2019.
Prior Publication US 2023/0364088 A1, Nov. 16, 2023
Int. Cl. A61K 31/506 (2006.01); A61K 31/4439 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61P 1/00 (2006.01); A61P 17/00 (2006.01); A61P 19/04 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 31/4439 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 17/00 (2018.01); A61P 19/04 (2018.01); A61P 35/00 (2018.01)] 15 Claims
OG exemplary drawing
 
1. A method of treating a melanoma having an NRAS mutation, comprising administering to an individual an effective amount of BI853520 or a pharmaceutically acceptable salt thereof thereby inhibiting the growth of the melanoma.